| Basics |
Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
|
| IPO Date: |
November 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.12B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.55 | 2.55%
|
| Avg Daily Range (30 D): |
$0.77 | 1.89%
|
| Avg Daily Range (90 D): |
$1.05 | 2.25%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.45M |
| Avg Daily Volume (30 D): |
.42M |
| Avg Daily Volume (90 D): |
.38M |
| Trade Size |
| Avg Trade Size (Sh.): |
102 |
| Avg Trade Size (Sh.) (30 D): |
44 |
| Avg Trade Size (Sh.) (90 D): |
44 |
| Institutional Trades |
| Total Inst.Trades: |
2,725 |
| Avg Inst. Trade: |
$2.52M |
| Avg Inst. Trade (30 D): |
$2.29M |
| Avg Inst. Trade (90 D): |
$2.3M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.94M |
| Avg Closing Trade (30 D): |
$3.56M |
| Avg Closing Trade (90 D): |
$3.44M |
| Avg Closing Volume: |
89.93K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.23
|
$.4
|
$.21
|
|
Diluted EPS
|
$-.23
|
$.39
|
$.2
|
|
Revenue
|
$ 52.6M
|
$ 75.38M
|
$ 237.22M
|
|
Gross Profit
|
$ 36.27M
|
$ 58.5M
|
$ 172.11M
|
|
Net Income / Loss
|
$ -11.25M
|
$ 19.81M
|
$ 10.36M
|
|
Operating Income / Loss
|
$ -12.79M
|
$ 18.48M
|
$ 4.52M
|
|
Cost of Revenue
|
$ 16.33M
|
$ 16.88M
|
$ 65.12M
|
|
Net Cash Flow
|
$ -5.34M
|
$ 14.7M
|
$ -1.82M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 16, 2013:
1:20
|
|
Feb 18, 2010:
1:8
|
|
